Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

AEOL-10150 (Aeolus).

Richard W Orrell1

  • 1Department of Clinical Neurosciences, Royal Free and University College Medical School, University College London, Rowland Hill Street, London NW3 2PF, UK. r.orrell@medsch.ucl.ac.uk

Current Opinion in Investigational Drugs (London, England : 2000)
|January 24, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acceptance and Commitment Therapy plus usual care for improving quality of life in people with motor neuron disease (COMMEND): a multicentre, parallel, randomised controlled trial in the UK.

Lancet (London, England)·2024
Same author

Dyspnea (breathlessness) in amyotrophic lateral sclerosis/motor neuron disease: prevalence, progression, severity, and correlates.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2024
Same author

Opinion: more mouse models and more translation needed for ALS.

Molecular neurodegeneration·2023
Same author

Author Correction: Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology.

Nature genetics·2022
Same author

Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology.

Nature genetics·2021
Same author

Association of Variants in the SPTLC1 Gene With Juvenile Amyotrophic Lateral Sclerosis.

JAMA neurology·2021

AEOL-10150, a novel antioxidant, is being developed for neurodegenerative diseases like amyotrophic lateral sclerosis (ALS). This small molecule is currently in a Phase I clinical trial, showing promise for treating ALS and other inflammatory conditions.

Area of Science:

  • Biochemistry
  • Neuroscience
  • Pharmacology

Background:

  • Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with limited treatment options.
  • Oxidative stress plays a significant role in the pathogenesis of ALS and other neurological disorders.
  • AEOL-10150 is a small-molecule antioxidant designed to mimic the function of superoxide dismutase.

Purpose of the Study:

  • To evaluate the safety and tolerability of AEOL-10150 in patients with ALS.
  • To explore the potential therapeutic effects of AEOL-10150 in neurodegenerative and inflammatory conditions.
  • To advance the development of AEOL-10150 as a subcutaneous treatment for ALS.

Main Methods:

  • Phase I clinical trial to assess safety and dosage of AEOL-10150 in ALS patients.

Related Experiment Videos

  • Subcutaneous administration of AEOL-10150.
  • Ongoing clinical development for ALS, stroke, spinal cord injury, lung inflammation, and mucositis.

    • Main Results:

    • AEOL-10150 is currently undergoing Phase I clinical trials for ALS.
    • The compound has shown potential as a treatment for various neurological and inflammatory conditions.
    • Aeolus (formerly Incara) is pursuing regulatory pathways, including Fast Track status.

    Conclusions:

    • AEOL-10150 represents a promising therapeutic candidate for ALS and other conditions associated with oxidative stress.
    • Further clinical trials are planned to establish efficacy and safety.
    • The development of AEOL-10150 targets significant unmet medical needs in neurology and inflammation.